Blockade of LAG-3, TIM-3, TIGIT, and VISTA have shown improved anti-tumor responses in preclinical models when combined with anti-CTLA-4 or anti-PD-1 therapy and are currently being evaluated in clinical trials. Here, PDCD1 is linked to neoplasm.